NO-NSAIDs are promising anticancer drugs, comprising an NSAID, an NO-releasing moiety,
and a spacer linking them. Although the effect of NO-NSAIDs on a wide variety of signaling …

Nitric oxide-donating aspirin (NO-ASA) is a promising agent for cancer prevention. Although
studied extensively, its molecular targets and mechanism of action are still unclear. S …

Nitric oxide-donating nonsteroidal anti-inflammatory drugs (NO-NSAIDs) consist of a
conventional NSAID to which an NO-releasing moiety is attached covalently, often via a …

Although non steroidal antiinflammatory drugs (NSAIDs) have been shown to be effective as
chemopreventive agents, important side-effects limit their clinical use. A promising novel …

The chemoprevention of colon cancer, the second leading cause of cancer-related deaths in
the United States, has been pursued actively during the last two decades. Methodological …

NO (nitric oxide) biology has provided the impetus for the development of anticancer agents
based on their ability to release NO. NO-NSAIDs (NO-donating non-steroidal anti …

Nitric oxide‐donating nonsteroidal anti‐inflammatory drugs (NO‐NSAIDs) represent a novel
class of compounds that hold promise as agents for the control of colon cancer. They are …

Nitric-oxide-donating nonsteroidal anti-inflammatory drugs (NO–NSAIDs), which consist of
an NSAID with an NO-donating moiety covalently attached to it, promise to contribute …

Nitric oxide-donating aspirin (NO-ASA) is a promising agent for the control of cancer, whose
mechanism of action remains unclear. NF-κB is an important signaling molecule in the …

The novel nitric oxide-donating nonsteroidal antiinflammatory drugs (NO-NSAIDs),
consisting of a traditional NSAID to which a NO releasing moiety is covalently attached, may …